Incidence rate (number and percentage) of patients with various adverse prognostic factors by arm (N = 84)
| . | 21/28 . | 28/28 . | . |
|---|---|---|---|
| . | (N = 43) . | (N = 41) . | Total . |
| Patients >6 lines of therapy, n (%) | 12 (28) | 7 (17) | 19 (23) |
| Refractory to*, n (%) | |||
| Lenalidomide | 36 (84) | 39 (95) | 75 (89) |
| Lenalidomide last prior therapy | 15 (35) | 11 (27) | 26 (31) |
| Bortezomib | 34 (79) | 34 (83) | 68 (81) |
| Both lenalidomide and bortezomib | 32 (74) | 32 (78) | 64 (76) |
| Last prior therapy | 36 (70) | 35 (68) | 71 (84.5) |
| FISH cytogenetics, n (%)† | N = 33 | N = 32 | |
| Deletion 17p | 6 (21) | 9 (33) | — |
| Translocation (4;14) | 2 (7) | 4 (17) | — |
| . | 21/28 . | 28/28 . | . |
|---|---|---|---|
| . | (N = 43) . | (N = 41) . | Total . |
| Patients >6 lines of therapy, n (%) | 12 (28) | 7 (17) | 19 (23) |
| Refractory to*, n (%) | |||
| Lenalidomide | 36 (84) | 39 (95) | 75 (89) |
| Lenalidomide last prior therapy | 15 (35) | 11 (27) | 26 (31) |
| Bortezomib | 34 (79) | 34 (83) | 68 (81) |
| Both lenalidomide and bortezomib | 32 (74) | 32 (78) | 64 (76) |
| Last prior therapy | 36 (70) | 35 (68) | 71 (84.5) |
| FISH cytogenetics, n (%)† | N = 33 | N = 32 | |
| Deletion 17p | 6 (21) | 9 (33) | — |
| Translocation (4;14) | 2 (7) | 4 (17) | — |